Immunology News
🇪🇺 EMAEMA breaking news and regulatory updates for BD, investors, and analysts
Showing 1–12 of 16 articles
Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment
EULAR 2026: Immutep's IMP761 Phase I Data Preview
HUTCHMED's Sovleplenib Receives Priority Review and Breakthrough Designation in China for Rare Blood Disorder
Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment
EMA Establishes Expert Panel to Strengthen COVID-19 mRNA Vaccine Trust Including Spikevax and Comirnaty
Artiva Biotherapeutics' AlloNK Receives FDA Fast Track Designation for Refractory Rheumatoid Arthritis Treatment
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors
Abivax Presents Obefazimod Phase 3 Data at Digestive Disease Week 2026
Roche's Gazyva Receives FDA Acceptance for Lupus Treatment Following Positive Phase III Trial Results
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial